The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride

Published:1 December 2006 DOI: 10.1016/j.jaad.2006.05.007 PMID: 17110217

Elise A. Olsen MD , Maria Hordinsky MD , David Whiting PhD , Dow Stough MD , Stuart Hobbs PharmD , Melissa L. Ellis PharmD , Timothy Wilson MS , Roger S. Rittmaster MD , for the Dutasteride Alopecia Research Team

Abstract

Background

Male pattern hair loss (MPHL) is a potentially reversible condition in which dihydrotestosterone is an important etiologic factor.

Objective

Our aim was to evaluate the efficacy of the type 1 and 2 5α-reductase inhibitor dutasteride in men with MPHL.

Methods

Four hundred sixteen men, 21 to 45 years old, were randomized to receive dutasteride 0.05, 0.1, 0.5 or 2.5 mg, finasteride 5 mg, or placebo daily for 24 weeks.

Results

Dutasteride increased target area hair count versus placebo in a dose-dependent fashion and dutasteride 2.5 mg was superior to finasteride at 12 and 24 weeks. Expert panel photographic review and investigator assessment of hair growth confirmed these results. Scalp and serum dihydrotestosterone levels decreased, and testosterone levels increased, in a dose-dependent fashion with dutasteride.

Limitations

The study was limited to 24 weeks.

Conclusion

Dutasteride increases scalp hair growth in men with MPHL. Type 1 and type 2 5α-reductase may be important in the pathogenesis and treatment of MPHL.